Advertisement

Breast Cancer Research and Treatment

, Volume 148, Issue 1, pp 1–5 | Cite as

Tamoxifen-associated skin reactions in breast cancer patients: from case report to literature review

  • Peter AndrewEmail author
  • Sabira Valiani
  • Jennifer MacIsaac
  • Hamid Mithoowani
  • Shailendra Verma
Review

Abstract

The purpose of this study was to firstly present the maiden case of tamoxifen-induced acute cutaneous lupus erythematosus (ACLE), and secondly, to broaden the discussion into a systematic review of the various tamoxifen-related skin changes documented in patients with breast cancer. We searched PubMed, Cochrane, Embase, CancerLit, Scopus, Web of Science, and Google Scholar databases using keywords to identify reported cases of tamoxifen-related cutaneous adverse events. Outcomes captured included type of cutaneous reaction, time to adverse event, pathologic mechanism, and possible treatment. From 17 clinical studies identified, over ten distinct types of adverse reactions of the skin were itemized. The character of these cutaneous events ranged from the relatively common hot flashes to the rare, but potentially life-threatening, Steven Johnson syndrome. Overall, tamoxifen is generally a well-tolerated hormone therapy with decades of supporting safety data. Based on current medical literature, we present the first case of tamoxifen-induced ACLE. Our clinical experience of managing this case revealed that despite its broad use and the frequency of associated skin reactions, there is a lack of concise information detailing the cutaneous adverse events associated with tamoxifen. The absence of summarized information concerning tamoxifen-related skin changes prompted us to perform a review herein.

Keywords

Breast cancer Drug-induced lupus Hypersensitivity Rash Skin Tamoxifen 

Notes

Acknowledgments

Authors wish to thank the Librarians at the Ottawa Hospital for their generous support towards rendering the availability of original articles. Specific gratitude extended to Ms. Johanne Gohier in this regard.

Conflicts of interest

The authors indicate no conflicts of interest.

References

  1. 1.
    Jordan VC (1997) Tamoxifen treatment for breast cancer: concept to gold standard. Oncology (Williston Park, NY) 11(2 Suppl 1):7–13Google Scholar
  2. 2.
    Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28(23):3784–3796. doi: 10.1200/jco.2009.26.3756 PubMedCrossRefGoogle Scholar
  3. 3.
    Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, Davidson NE, Decensi A, Fabian C, Ford L, Garber J, Katapodi M, Kramer B, Morrow M, Parker B, Runowicz C, Vogel VG 3rd, Wade JL, Lippman SM (2013) Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31(23):2942–2962. doi: 10.1200/jco.2013.49.3122 PubMedCrossRefGoogle Scholar
  4. 4.
    Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER et al (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320(8):479–484. doi: 10.1056/nejm198902233200802 PubMedCrossRefGoogle Scholar
  5. 5.
    Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Muller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrutia G, Valentini M, Wang Y, Peto R (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816. doi: 10.1016/s0140-6736(12)61963-1 PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Craig JV (1994) The development of tamoxifen for breast cancer therapy. In: Craig JV (ed) Long-term tamoxifen treatment for breast cancer. Wisconsin Press, Wisconsin, pp 4–26Google Scholar
  7. 7.
    Brahmi SA, Benjelloun H, Bouyahyaoui Y, Mernissi FZ, El Mesbahi O (2011) Delayed maculopapular eruption induced by tamoxifen. A case report. J Cancer Sci Ther 3(4):79–80CrossRefGoogle Scholar
  8. 8.
    Descamps V, Bouscarat F, Boui M, Marck Y, Lebrun-Vignes B, Crickx B, Belaich S (1999) Delayed appearance of maculopapular eruptions induced by tamoxifen. Ann Dermatol Venereol 126(10):716–717PubMedGoogle Scholar
  9. 9.
    Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86(7):527–537PubMedCrossRefGoogle Scholar
  10. 10.
    Gatti FR, Pires MC (2008) Pseudolymphoma as adverse reaction to tamoxifen. J Eur Acad Dermatol Venereol 22(8):1004–1005. doi: 10.1111/j.1468-3083.2007.02474.x PubMedCrossRefGoogle Scholar
  11. 11.
    Ingle JN, Green SJ, Ahmann DL, Edmonson JH, Nichols WC, Frytak S, Rubin J (1982) Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide. Trial II: aminoglutethimide in patients with prior tamoxifen exposure. Cancer Res 42(8 Suppl):3461s–3467sPubMedGoogle Scholar
  12. 12.
    Wiggans RG, Woolley PV, Smythe T, Hoth D, Macdonald JS, Green L, Schein PS (1979) Phase-II trial of tamoxifen in advanced breat cancer. Cancer Chemother Pharmacol 3(1):45–48PubMedCrossRefGoogle Scholar
  13. 13.
    Agarwal R, Peters TJ, Coombes RC, Vigushin DM (2002) Tamoxifen-related porphyria cutanea tarda. Med Oncol (Northwood, London, England) 19(2):121–123. doi: 10.1385/mo:19:2:121 CrossRefGoogle Scholar
  14. 14.
    Bostrom A, Sjolin-Forsberg G, Wilking N, Bergh J (1999) Radiation recall–another call with tamoxifen. Acta Oncol (Stockholm, Sweden) 38(7):955–959CrossRefGoogle Scholar
  15. 15.
    Kim SW, Yoon HS (2009) Tamoxifen-induced melasma in a postmenopausal woman. J Eur Acad Dermatol Venereol 23(10):1199–1200Google Scholar
  16. 16.
    Cruz MJ, Alves S, Baudrier T, Azevedo F (2010) Porphyria cutanea tarda induced by tamoxifen. Dermatol Online J 16(9):2PubMedGoogle Scholar
  17. 17.
    Fumal I, Danchin A, Cosserat F, Barbaud A, Schmutz JL (2005) Subacute cutaneous lupus erythematosus associated with tamoxifen therapy: two cases. Dermatology (Basel, Switzerland) 210(3):251–252. doi: 10.1159/000083798 CrossRefGoogle Scholar
  18. 18.
    Kundranda MN, Daw HA (2006) Tamoxifen-induced radiation recall dermatitis. Am J Clin Oncol 29(6):637–638. doi: 10.1097/01.coc.0000189693.23157.8d PubMedCrossRefGoogle Scholar
  19. 19.
    Malina L, Michalikova H, Hussarova L (1999) Porphyria cutanea tarda after antineoplastic drugs. Cas Lek Cesk 138(17):536–538PubMedGoogle Scholar
  20. 20.
    Singer EA, Warren RD, Pennanen MF, Collins BT, Hayes DF (2004) Tamoxifen-induced radiation recall dermatitis. Breast J 10(2):170–171PubMedCrossRefGoogle Scholar
  21. 21.
    Rousset-Jablonski C, Thalabard JC, Gompel A (2009) Tamoxifen contraindicated in women with hereditary angioedema? Ann Oncol 20(7):1281–1282. doi: 10.1093/annonc/mdp295 PubMedCrossRefGoogle Scholar
  22. 22.
    Inaloz HS, Deveci E, Inaloz SS, Unal B, Eralp A, Can I (2002) The effects of tamoxifen on rat skin. Eur J Gynaecol Oncol 23(1):50–52PubMedGoogle Scholar
  23. 23.
    Drago F, Arditi M, Rebora A (1990) Tamoxifen and purpuric vasculitis. Ann Intern Med 112(12):965–966Google Scholar
  24. 24.
    Baptista MZ, Prieto VG, Chon S, Hortobagyi GN, Esteva FJ (2006) Tamoxifen-related vasculitis. J Clin Oncol 24(21):3504–3505Google Scholar
  25. 25.
    Candelaria M, Hurtado-Monroy R, Vargas-Viveros P, Carrillo-Muñnoz S, Duenas-Gonzalez A (2007) Tamoxifen-associated vasculitis in a breast cancer patient. World J Surg Oncol 5:9Google Scholar
  26. 26.
    Betto P, Gennari E, Germi L, Bonoldi E, Scalco G, Tosti A (2008) Tamoxifen and purpuric vasculitis: a case report. J Eur Acad Dermatol Venereol 22(6):762–763Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Peter Andrew
    • 1
    Email author
  • Sabira Valiani
    • 2
  • Jennifer MacIsaac
    • 3
  • Hamid Mithoowani
    • 4
  • Shailendra Verma
    • 1
  1. 1.Division of Medical OncologyUniversity of OttawaOttawaCanada
  2. 2.Division of Critical CareUniversity of OttawaOttawaCanada
  3. 3.Division of DermatologyUniversity of OttawaOttawaCanada
  4. 4.Division of Internal MedicineOttawaCanada

Personalised recommendations